Argenta Discovery and Zafgen Announce Contract Drug Discovery Collaboration in Obesity
News Jan 30, 2009
Argenta Discovery Ltd. and Zafgen, Inc. have announced that they have entered into major drug discovery collaboration.
Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism and pharmacokinetics to accelerate development candidate nomination for one of Zafgen’s therapeutics programs for obesity.
Dr. Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen said, "We are looking forward to working with Argenta Discovery to accelerate one of our important discovery programs towards development. They have a solid and successful track record in drug discovery and through their contracts have placed many compounds into clinical development. Working closely with the Argenta team, we are confident that we will rapidly identify and advance drug candidates for Zafgen.”
Dr. Hughes continued, “Obesity is a global epidemic, affecting an estimated 400 million people worldwide, which also leads to an increasing prevalence of obesity-related co-morbidities, including type 2 diabetes. Zafgen’s unique approach of discovering and developing anti-obesity agents that target adipose vasculature to shrink fat cells to help the body sustain a lean, healthy state offers the possibility of a real breakthrough in this area, where there is considerable unmet medical need.”
Commenting on the agreement, Dr. Christopher Ashton, Argenta’s Chief Executive Officer, said, “We are delighted that Zafgen has chosen to collaborate with Argenta on this exciting program. Their decision to work with us is based on our contract research team’s acknowledged expertise, and our ability to offer a fully integrated approach to drug discovery. We look forward to building a successful and long-term partnership with Zafgen.”
Financial terms of the deal were not disclosed, but the agreement does provide options to expand the relationship.
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.